OTCMKTS: $BAYRY A Breakthrough for NSCLC Patients The landscape of cancer treatment continues to evolve with the recent news that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hyrnuo (sevabertinib). This development marks a significant shift for patients diagnosed with non-small cell lung cancer (NSCLC). What is Hyrnuo? Hyrnuo represents the…